Lineagen, Inc. to Showcase $15 Million Series 'B' Round at the 9th Annual Biotechnology Industry Organization (BIO) Investor Forum  
10/4/2010 12:06:44 PM

SALT LAKE CITY--(BUSINESS WIRE)--Lineagen, Inc. (, a specialty diagnostics firm offering high-value genetic testing and consultative healthcare services for Autism Spectrum Disorders (ASD), today announced that Dr. Michael S. Paul, President and Chief Executive Officer, will present details of the company’s $15 Million Series ‘B’ investment round at the 9th Annual BIO Investor Forum. Dr. Paul will present at 4:00 p.m. Pacific Time, on Tuesday, October 5th in the Marina Room of the Palace Hotel in San Francisco, CA.